Cardiac action potential action potential (see phase 2, below) and is a fundamental step in cardiac excitation-contraction coupling. There are important physiological differences between the cells that spontaneously generate the action potential (pacemaker cells; e.g. SAN) and those that simply conduct it (non-pacemaker cells; e.g. ventricular myocytes). The specific differences in the types of ion channels expressed and mechanisms by which they are activated results in differences in the configuration of the action potential waveform, as shown in figure 2. The standard model used to understand the cardiac action potential is that of the ventricular myocyte. Outlined below are the five phases of
Milrinone of the cardiomyocytes therefore increasing the rate at which cells can depolarize and generate contraction. PKA also phosphorylates components on myofilaments allowing actin and myosin to interact more easily and thus increasing contractility and the inotropic state of the heart. Milrinone allows stimulation of cardiac function independently of β-adrenergic receptors which appear to be down-regulated in those with heart failure. In recent years many studies have been performed showing that milrinone use may present potential adverse side effects in heart failure patients. Milrinone Milrinone, commonly known and marketed under the brand name Primacor, is a medication used in patients who